Why AbbVie Stock Stumbled Today Despite the Earnings Beat

By almost any measure, AbbVie (NYSE: ABBV) shares should have risen Friday. The pharmaceutical giant delivered first-quarter sales and earnings results that topped estimates. The decline in sales of multi-indication immunosuppressive drug Humira -- a natural result of its loss of patent…#humira #abbvie #rinvoq #imbruvica #jamesbrumley #earningsbeat
Source: Reuters: Health - Category: Consumer Health News Source Type: news